The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer

Urology. 2019 Aug:130:1-12. doi: 10.1016/j.urology.2019.04.004. Epub 2019 Apr 12.

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an excellent diagnostic tool, that may drastically impact the management of a large number of patients with primary and recurrent CaP.

Publication types

  • Review

MeSH terms

  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Membrane Glycoproteins*
  • Multimodal Imaging
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Organometallic Compounds*
  • Positron Emission Tomography Computed Tomography / methods*
  • Positron-Emission Tomography*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / therapy
  • Radiopharmaceuticals*
  • Salvage Therapy / methods

Substances

  • Gallium Isotopes
  • Gallium Radioisotopes
  • Membrane Glycoproteins
  • Organometallic Compounds
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Prostate-Specific Antigen